CERo Therapeutics Holdings, Inc Common Stock

Yahoo Finance • 9 days ago

CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort

Third patient in the first cohort is now advancing through protocol-defined evaluations as Company anticipates additional results from second dosing of second patient in the cohort SOUTH SAN FRANCISCO, Calif, Sept. 22, 2025 (GLOBE NEWSW... Full story

Yahoo Finance • 22 days ago

CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041

Additional patent granted from the Japanese patent office now results in 20 granted patents and allowed applications covering the compound and its underlying technology SOUTH SAN FRANSCISCO, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- C... Full story

Yahoo Finance • 23 days ago

The trading volume of these stocks is deviating from the norm in today's session.

Let's have a look at the stocks with an unusual volume in today's session. [unusualvolume] UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT HOUR [https://www.chartmill.com/stock/quote/HOUR/profile] 52.9% So far 51.7M shares of... Full story

Yahoo Finance • 23 days ago

CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia

Study investigator of Phase 1 trial presented poster at Society of Hematologic Oncology 13th annual conference highlighting original study protocol SOUTH SAN FRANSCISCO, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Hold... Full story

Yahoo Finance • 26 days ago

CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)

Regulatory milestone adds to its existing Orphan Drug Designation, creating additional regulatory and financial advantages for the Company’s lead cancer immunotherapy program SOUTH SAN FRANSCISCO, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE)... Full story

Yahoo Finance • 2 months ago

CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236

Second patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update on first patient pharmacokinetic results SOUTH SAN FRANSCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CERo... Full story

Yahoo Finance • 2 months ago

Cero Therapeutics registers up to 12.5M shares for potential sale under equity agreement with Keystone

* Cero Therapeutics (NASDAQ:CERO [https://seekingalpha.com/symbol/CERO]) has filed a prospectus to allow the potential sale of up to 12.5M shares of common stock to Keystone Capital Partners. * The agreement gives Cero access to capita... Full story

Yahoo Finance • 3 months ago

Cero Therapeutics regains Nasdaq compliance after bid price deficiency

Cero Therapeutics Holdings, Inc. (NASDAQ:CERO) announced on Monday that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Capital Market, according to a statement based on a recent S... Full story

Yahoo Finance • 3 months ago

Cero Therapeutics adds institutional investors in Series D preferred stock sale

Cero Therapeutics Holdings, Inc. (NASDAQ:CERO), currently trading at $9.63 and identified as undervalued according to InvestingPro analysis, amended its securities purchase agreement on Wednesday to include new institutional investors in i... Full story

Yahoo Finance • 3 months ago

CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236

SOUTH SAN FRANSCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an immunotherapy company developing the next generation of engineered T cell therapeutics targeti... Full story

Yahoo Finance • 3 months ago

Sector Update: Health Care Stocks Retreat Late Afternoon

Health care stocks declined late Tuesday afternoon with the NYSE Health Care Index dropping 1.7% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 months ago

CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)

SOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of  engineered T cell... Full story

Yahoo Finance • 4 months ago

Cero Therapeutics announces 1-for-20 reverse stock split

CERo Therapeutics (CERO) announced that its board of directors has determined to effect a one-for-twenty reverse stock split of the Company’s common stock, par value $0.0001 per share. The reverse stock split will take effect at 12:01 a.m.... Full story

Yahoo Finance • 4 months ago

CERo Therapeutics announces 1-for-20 reverse stock split effective June 13

* CERo Therapeutics (NASDAQ:CERO [https://seekingalpha.com/symbol/CERO]) will implement a 1-for-20 reverse stock split on June 13, 2025. * The split reduces outstanding common shares from ~10.32M to ~516,092. * The stock will begin t... Full story

Yahoo Finance • 4 months ago

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

SOUTH SAN FRANSCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell t... Full story

Yahoo Finance • 4 months ago

CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing

SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that em... Full story

Yahoo Finance • 4 months ago

CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company’s Lead Compound CER-1236

Results in 18 Issued Patents and Allowed Patent Applications Internationally with Nine Total Patent Families SOUTH SAN FRANSCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or th... Full story

Yahoo Finance • 4 months ago

CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations

CERO Chief Medical Officer to discuss trial protocol in poster at the American Society for Clinical Oncology Conference The first patient has been dosed and is advancing through protocol-defined evaluations SOUTH SAN FRANSCISCO, Calif.,... Full story

Yahoo Finance • 5 months ago

CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing

SOUTH SAN FRANCISCO, Calif, April 22, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that e... Full story

Yahoo Finance • 6 months ago

CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company’s Lead Compound CER-1236

Results in 17 Issued and Allowed Patent Applications Internationally with Nine Total Patent Families SOUTH SAN FRANSCISCO, Calif, April 10, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Compan... Full story